about
Intracellular ion channels and cancerInsights into the carboxyltransferase reaction of pyruvate carboxylase from the structures of bound product and intermediate analogsHeterogeneity of glycolysis in cancers and therapeutic opportunities.Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summaryThe reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cellsAntitumoural activity of a cytotoxic peptide of Lactobacillus casei peptidoglycan and its interaction with mitochondrial-bound hexokinaseMetabolic engineering and classical selection of the methylotrophic thermotolerant yeast Hansenula polymorpha for improvement of high-temperature xylose alcoholic fermentation.Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cellsLarge-scale identification and analysis of suppressive drug interactions.Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid TumorsInhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis.By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancerTyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes.Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: Implication in designing of novel anticancer therapeutic strategies.MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.3-bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth.Proapoptotic Role of Potassium Ions in Liver CellsCritical Role of Glucose Metabolism in Rheumatoid Arthritis Fibroblast-like Synoviocytes.Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides.Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.Mitochondrial ion channels as oncological targets.The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.3-Bromopyruvate induces rapid human prostate cancer cell death by affecting cell energy metabolism, GSH pool and the glyoxalase system.Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy.Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate.Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer3-bromopyruvate inhibits glycolysis, depletes cellular glutathione, and compromises the viability of cultured primary rat astrocytes.Glycolytic enzyme upregulation and numbness of mitochondrial activity characterize the early phase of apoptosis in cerebellar granule cells.Impaired mitochondrial functions contribute to 3-bromopyruvate toxicity in primary rat and mouse hepatocytes.Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells.Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma.The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria.Hepatotoxicity and nephrotoxicity of 3-bromopyruvate in mice.3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.
P2860
Q27008995-BF70BBB5-47D5-45BE-873A-2F83F4FF6404Q27680459-3F013AE1-6579-40CC-8CD2-8931882DD6DAQ27693375-B87EE275-A954-4E51-8CBC-8F2CBB9DA4DAQ28087554-6130D90C-E8EF-4A6C-9EF0-3AE62FBBE0D9Q28544747-AA8A6973-DB9F-4842-ADA1-BFE39EA2FDE0Q28831079-524B5ABD-86CE-4C37-8443-9FEAB750D3CBQ34091389-C9FCDE1D-E80B-404F-8546-F58573D9BDE9Q34104182-9B9E5D60-95ED-4BD3-92A4-FBFF0E66D9C9Q34179999-3D9DFBAD-B2B0-4749-919F-334832FD1143Q34503166-B254B454-073C-4ABA-B1A2-2B2F384B8A24Q34799147-45E413AD-92AE-40E4-83C0-A0E71CFDCB5BQ35845149-D8B56241-290F-4899-B11D-950052065EE2Q35848673-04F9A136-A83A-4BE0-B10A-690D83206F46Q35955419-70B52885-F7A3-4870-A803-C4BE2A10993EQ35987880-29EC6D3A-CE33-4652-AD3C-ACA51655CDE5Q36016760-3528B4C8-C47C-4123-A683-4AD9D27F3FD7Q36099121-873A9C55-3B7C-48BC-9013-E4C7AB93D97FQ36360728-6D90DF53-F401-4205-93C8-95AB27FDE0E9Q36489907-7BD473B3-0B9D-4342-AEF1-064A48F5A54AQ36572127-9ECE0F81-A763-44EE-9E68-E895B1DE3BAAQ36741184-14090179-0CD7-4662-9B03-4203C6579080Q37131464-63BD9568-4CC8-4FF7-9F37-C539C6BB5029Q37247546-7B449910-5240-44E0-A666-547F1A5E959FQ37662284-9278BB1B-04D1-42C0-8441-CC12459E3311Q38182357-CC5B8831-0ADA-4712-8C3C-B825726B6383Q38612793-B152B654-5B14-48FC-98CC-FC22B1151119Q38837920-2C20E041-3CE3-43BC-AB28-BD7476D48E50Q38863836-DD645A31-0BC0-4717-BA8F-6ED499132271Q38946644-989962A1-5A6B-4CFD-B300-9B4503F5D266Q39125005-58A5EB3C-800C-4E2C-8B08-FF4CAAFD59DAQ39284220-20CE06C7-B40A-4993-89FE-6C4BDAD8403EQ41779719-D955644F-E5E3-4F44-8069-6CDF11461FDEQ44176675-4319C5FE-8B66-4665-8458-32A473D5B94CQ44721612-A9FA8574-1460-44A3-9700-9D02E7915E0FQ46501130-26BE0453-2CF6-4F07-B538-BF6336AD5C48Q46617301-EFF9E4FB-C2DF-4214-B58A-FD1F1153B948Q47109133-A720B702-46EB-4319-A627-6B85AC24CF79Q48560205-75AC46C0-DB29-4C25-8258-22FFE4B61EEDQ52812685-FF8A70EC-2C25-46CA-B75F-16F48E614783Q54526090-D810C36E-CB31-4AED-A7AE-0308CFF0B56B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
3-Bromopyruvate: targets and outcomes.
@en
3-Bromopyruvate: targets and outcomes.
@nl
type
label
3-Bromopyruvate: targets and outcomes.
@en
3-Bromopyruvate: targets and outcomes.
@nl
prefLabel
3-Bromopyruvate: targets and outcomes.
@en
3-Bromopyruvate: targets and outcomes.
@nl
P2860
P1476
3-Bromopyruvate: targets and outcomes.
@en
P2093
Maria C Shoshan
P2860
P2888
P356
10.1007/S10863-012-9419-2
P577
2012-02-01T00:00:00Z